SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of disaggregated revenue

The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2018, 2017, and 2016:

	For the Years Ended December 31,
	2018		2017		2016
Prescription vitamins	$	15,041,259	$	16,744,831	$	18,854,984
IMVEXXY®		1,058,201		—		—
OTC products		—		32,882		501,466
Net revenue	$	16,099,460	$	16,777,713	$	19,356,450

Schedule of potentially dilutive securities

The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.

	As of December 31,
	2018		2017		2016
Stock options		20,872,824		23,365,225		21,767,854
Warrants		3,007,571		3,115,905		12,060,071
Restricted stock awards		1,040,000		—		—
		24,920,395		26,481,130		33,827,925